Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chikuma Hamada

Showing results (31-40 of 96) with videos related to

Pageof 10
Sort By:
Chemotherapy|August 18, 2017
The Effect of Tegafur-Uracil on Survival in T Categories as Defined in the Eighth Edition of the TNM Classification: An Exploratory Analysis of Postoperative Adjuvant Tegafur-Uracil on Survival in Patients with Adenocarcinoma of the LungMasahiro Tsuboi, Chikuma Hamada, Harubumi Kato, et al.
Bioinformatics and Biology Insights|October 9, 2009
A new test statistic based on shrunken sample variance for identifying differentially expressed genes in small microarray experimentsAkihiro Hirakawa, Yasunori Sato, Chikuma Hamada, et al.
Statistics in Medicine|September 7, 2005
Effective number of subjects and number of raters for inter-rater reliability studiesYuki Saito, Takashi Sozu, Chikuma Hamada, et al.
Anticancer Research|October 7, 2017
A Proposal for Progression-Free Survival Assessment in Patients with Early Progressive CancerTakanori Tanase, Chikuma Hamada, Takayuki Yoshino, et al.
Statistics in Medicine|July 16, 2013
An efficient and robust method for analyzing population pharmacokinetic data in genome-wide pharmacogenomic studies: a generalized estimating equation approachKengo Nagashima, Yasunori Sato, Hisashi Noma, et al.
Journal of Biopharmaceutical Statistics|February 9, 2018
Two-stage approach based on zone and dose findings for two-agent combination Phase I/II trialsFumiya Shimamura, Chikuma Hamada, Shigeyuki Matsui, et al.
Journal of Biopharmaceutical Statistics|February 26, 2010
Optimal two-stage designs allowing flexibility in number of subjects for phase II clinical trialsNobuyuki Masaki, Tatsuki Koyama, Isao Yoshimura, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|February 27, 2007
Dose-response effect of flecainide in patients with symptomatic paroxysmal atrial fibrillation and/or flutter monitored with trans-telephonic electrocardiography: a multicenter, placebo-controlled, double-blind trialHirotsugu Atarashi, Satoshi Ogawa, Hiroshi Inoue, et al.
Expert Opinion on Investigational Drugs|November 12, 2010
Clinical pharmacology study of the corticosteroid nasal spray dexamethasone cipecilate (NS-126): examination of the durability of efficacy in the nasal induction testMinoru Gotoh, Kimihiro Okubo, Minoru Okuda, et al.
Contemporary Clinical Trials|June 30, 2006
Minimization method for balancing continuous prognostic variables between treatment and control groups using Kullback-Leibler divergenceAkira Endo, Fumio Nagatani, Chikuma Hamada, et al.
Pageof 10

Showing results (31-40 of 96) with videos related to

Sort By:
Pageof 10
Chemotherapy|August 18, 2017
The Effect of Tegafur-Uracil on Survival in T Categories as Defined in the Eighth Edition of the TNM Classification: An Exploratory Analysis of Postoperative Adjuvant Tegafur-Uracil on Survival in Patients with Adenocarcinoma of the LungMasahiro Tsuboi, Chikuma Hamada, Harubumi Kato, et al.
Bioinformatics and Biology Insights|October 9, 2009
A new test statistic based on shrunken sample variance for identifying differentially expressed genes in small microarray experimentsAkihiro Hirakawa, Yasunori Sato, Chikuma Hamada, et al.
Statistics in Medicine|September 7, 2005
Effective number of subjects and number of raters for inter-rater reliability studiesYuki Saito, Takashi Sozu, Chikuma Hamada, et al.
Anticancer Research|October 7, 2017
A Proposal for Progression-Free Survival Assessment in Patients with Early Progressive CancerTakanori Tanase, Chikuma Hamada, Takayuki Yoshino, et al.
Statistics in Medicine|July 16, 2013
An efficient and robust method for analyzing population pharmacokinetic data in genome-wide pharmacogenomic studies: a generalized estimating equation approachKengo Nagashima, Yasunori Sato, Hisashi Noma, et al.
Journal of Biopharmaceutical Statistics|February 9, 2018
Two-stage approach based on zone and dose findings for two-agent combination Phase I/II trialsFumiya Shimamura, Chikuma Hamada, Shigeyuki Matsui, et al.
Journal of Biopharmaceutical Statistics|February 26, 2010
Optimal two-stage designs allowing flexibility in number of subjects for phase II clinical trialsNobuyuki Masaki, Tatsuki Koyama, Isao Yoshimura, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|February 27, 2007
Dose-response effect of flecainide in patients with symptomatic paroxysmal atrial fibrillation and/or flutter monitored with trans-telephonic electrocardiography: a multicenter, placebo-controlled, double-blind trialHirotsugu Atarashi, Satoshi Ogawa, Hiroshi Inoue, et al.
Expert Opinion on Investigational Drugs|November 12, 2010
Clinical pharmacology study of the corticosteroid nasal spray dexamethasone cipecilate (NS-126): examination of the durability of efficacy in the nasal induction testMinoru Gotoh, Kimihiro Okubo, Minoru Okuda, et al.
Contemporary Clinical Trials|June 30, 2006
Minimization method for balancing continuous prognostic variables between treatment and control groups using Kullback-Leibler divergenceAkira Endo, Fumio Nagatani, Chikuma Hamada, et al.
Pageof 10